Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

X submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which is subject to acceptance by the FDA. Additionally, a marketing authorization application (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the European Medicines Agency (EMEA).

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in a Phase 1 clinical trial. The objective of the development program for NGX-1998 is to determine its ability to provide protracted pain relief from a single treatment. As a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. NGX-1998 is being developed with the goal of it becoming a product that has the potential to be used by a broad spectrum of the physician population. NGX-1998 was previously studied in two Phase 1 studies in healthy volunteers conducted under an exploratory investigational new drug application.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, possible approval of NeurogesX' product candidates by the FDA or EMEA; estimations of the PDUFA date timing; plans and ability for commercial launch of NGX-4010; the sufficiency of cash resources to fund operations into 2010; plans for, and the potential timing of, establishment of commercialization partnerships in Europe and the United States, and th
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 30, 2014, after market close on Thursday, August 14, 2014 ... the market opening on Friday, August 15, 2014, at 8:00 ... Standard Time) to review the Company,s financial results and provide ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... , , , , , ... Tianyin,Pharmaceutical Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier,of modernized traditional Chinese ... second quarter ended December 31, 2009 . , , ... 24.8% to $2.6 Million with adjusted EPS of ...
... ... on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to ... ... Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the ...
... , , BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. ... it will participate at the,following investor conferences in March 2010 : , , Investor ... Location, Rodman & Renshaw Annual ... Investment ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 8Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 10Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 11Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 12Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 13Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 14Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 15Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 16Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 17Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3China Medical Technologies to Participate Investor Conferences in March 2010 2
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
(Date:7/25/2014)... , July 25, 2014 Biometrics ... are turning to digital technology for online & commerce ... Google Inc. (NASDAQ: GOOG ), LifeLock Inc. ... V ), Apple Inc. (NASDAQ: AAPL ... Inc., (OTCQB: NXTD) a biometric authentication company focused on ...
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... higher IQ and are more likely to go on to ... Sahlgrenska Academy and Sahlgrenska University Hospital. The results were ... Academy of Sciences ( PNAS ). The study involved ... between 1950 and 1976. The research group analysed the results ...
... , , REDWOOD CITY, Calif., ... identity and authentication solutions, today announced an agreement with ... biometric fingerprint technology on IBM SurePOS 500 retail systems. ... more easily and quickly identify users so that specific ...
... scientist from the University of Salamanca and another from Yale ... behaviour of Acanthodactylus beershebensis , a lizard species from ... study, these reptiles move less and catch less mobile and ... Many theoretical models had predicted this result, but until now ...
Cached Biology News:Young adults who exercise get higher IQ 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Lizards change their diet to avoid predators 2
... TOPO Cloning Kits for Sequencing allow 5-minute cloning ... contain TOPO Cloning vectors with primer sites located ... PCR product insertion site. This minimizes the amount ... before reaching the sequence of your insert.vectors are ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Request Info...
Biology Products: